Research Article

Characterization of the ZDSD Rat: A Translational Model for the Study of Metabolic Syndrome and Type 2 Diabetes

Richard G. Peterson,¹ Charles V. Jackson,¹ Karen Zimmerman,¹ Willem de Winter,² Norman Huebert,³ and Michael K. Hansen³

¹*PreClinOmics, Inc., 7918 Zionsville Road, Indianapolis, IN 46268, USA*

²*Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium*

³*Janssen Research & Development, LLC, Spring House, PA 19477, USA*

Correspondence should be addressed to Richard G. Peterson; rpeterson@preclinomics.com

Received 30 June 2014; Revised 5 September 2014; Accepted 16 September 2014

Academic Editor: Norihide Yokoi

Copyright © 2015 Richard G. Peterson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Metabolic syndrome and T2D produce significant health and economic issues. Many available animal models have monogenic leptin pathway mutations that are absent in the human population. Development of the ZDSD rat model was undertaken to produce a model that expresses polygenic obesity and diabetes with an intact leptin pathway. A lean ZDF rat with the propensity for beta-cell failure was crossed with a polygenetically obese Crl:CD (SD) rat. Offspring were selectively inbred for obesity and diabetes for >30 generations. In the current study, ZDSD rats were followed for 6 months; routine clinical metabolic endpoints were included throughout the study. In the prediabetic metabolic syndrome phase, ZDSD rats exhibited obesity with increased body fat, hyperglycemia, insulin resistance, dyslipidemia, glucose intolerance, and elevated HbA1c. As disease progressed to overt diabetes, ZDSD rats demonstrated elevated glucose levels, abnormal oral glucose tolerance, increases in HbA1c levels, reductions in body weight, increased insulin resistance with decreasing insulin levels, and dyslipidemia. The ZDSD rat develops prediabetic metabolic syndrome and T2D in a manner that mirrors the development of metabolic syndrome and T2D in humans. ZDSD rats will provide a novel, translational animal model for the study of human metabolic diseases and for the development of new therapies.

1. Introduction

Metabolic syndrome affects a significant proportion of the population and is becoming increasingly more prevalent in adolescents [1–4]. The syndrome embodies many components including central obesity, insulin resistance, dyslipidemia, and hypertension [3, 5]. In addition, the syndrome features a chronic low grade inflammatory state, vascular endothelial dysfunction, and a prothrombotic environment [3]. Long standing metabolic syndrome predisposes an individual to type 2 diabetes (T2D), atherosclerosis, microvasculature disease (of retina), stroke, renal injury, and neuropathy [5]. Due to the complicated mechanisms involved in the syndrome and its sequelae, current clinical standard of care embodies polypharmacological therapeutics aimed at controlling atherogenic dyslipidemia, hyperglycemia, and hypertension as well as intervening in secondary conditions

such as renal dysfunction, stroke, and microvascular disease related to retinopathy. Development of new chemical entities with the potential to control more than one risk factor is hampered by the paucity of highly translational animal models.

The most frequently used rat and mouse models for obesity, metabolic syndrome, and T2D have defects in the leptin pathway. The Zucker diabetic fatty (ZDF) has been a gold standard for this disease complex and as such has many of the characteristics of the human condition but it becomes obese due a leptin receptor defect and becomes diabetic before the animals are mature. To circumvent these ZDF complications, the ZDSD/Pco (ZDSD) rat has been developed to be a more translational model of obesity, metabolic syndrome, and diabetes and to aid the study of these conditions and the development of drugs that could assist in control and treatment. The model was developed by crossing a homozygous lean Zucker diabetic fatty (ZDF) male rat with a substrain of

the Crl:CD (SD) rats that had been selectively bred for high fat diet induced obesity [6, 7]. The standard Crl:CD (SD) rat is a substrain of SD rats that is significantly heavier and more obese than other lines of SD rats; a percentage of these rats is very susceptible to develop obesity, fed high fat diets [6, 7]. The original design was to combine the defect in β -cell gene transcription that is found in lean and obese ZDF rats [8] with the obesity of the Crl:CD (SD) model to produce an obese diabetic model that preserves the critical leptin pathway. The animals were fed regular rodent chow (Purina 5008) during the 12 years of the model development process. The offspring from the initial crosses were screened and selected for obesity, the propensity to become diabetic and the expression of the other characteristics of metabolic syndrome. This model has been selectively inbred for >30 generations.

In the current study, ZDSD rats were followed for 6 months; clinically relevant metabolic endpoints were included throughout the study to extensively characterize the phenotype and development of metabolic disease. The authors believe that the ZDSD rat displays a phenotype with close similarity to metabolic syndrome/T2D in humans further representing a “one rat, many models” tool that will enable the study of early metabolic dysregulation, overt diabetes, and late stage complications of T2D in one rat. It is the sum of the presence of all the characteristics of the human prediabetic state, T2D, and the growing number of associated comorbidities that creates the belief that the ZDSD rat is highly translational to the human condition. It is our belief that this model will reduce development and clinical costs and facilitate discovery of new agents with potential to impact multiple components of the disease. This study was designed to follow a cohort of male ZDSD rats from early in life and as they progress through obesity/metabolic syndrome into full T2D with beta cell failure. The study objectives included comparison of the model's disease progression to the development of diabetes in the human condition. This paper will be followed by a publication that will use these pieces of data to compare this progression in the ZDSD rat to what occurs in the human condition using a model similar to a published paper [9].

2. Research Design and Methods

2.1. Animals. Twenty-four male ZDSD rats (ZDSD/Pco) of comparable body weight were sourced at 6 weeks of age for the study (PreClinOmics Inc., Indianapolis, IN, USA). Animals were housed 2 per cage, fed Purina 5008 chow, and given water *ad libitum* for the duration of the study unless otherwise noted.

2.2. Definitions of Diabetic State. The definition of the permanent onset of diabetes in this model is quite simple, two subsequent weekly morning glucose readings of over 250 mg/dL. When this occurs, the animals will consistently continue to remain hyperglycemic and continue to get more overtly diabetic. For the purposes of this publication, three metabolic states are defined and used to describe the progressive disease states of the model that are typically used in describing the human conditions: (1) metabolic syndrome/prediabetic

hyperglycemia: fed/fasted glucose levels above 125 mg/dL, 50% increase in glucose AUC in the OGTT and a 25% increase in HbA1c; (2) diabetic: fed glucose levels above 250 mg/dL, >100% increase in HbA1c and a >200% increase in AUC in the OGTT; and (3) overt diabetes: equaling or exceeding values in (2) above decreases in insulin levels and weight loss. Depending on the methodology used for glucose measurements in an experiment, the actual glucose levels may vary.

2.3. Assays. Body weight was recorded and whole blood was collected every 2 weeks at 6 a.m. for purposes of obtaining fed analyte values. The whole blood (nonfasted samples) was collected by tail clip at 6 a.m. between 7–31 weeks of age for assessment of fed glucose levels using StatStrips (StatStrip Xpress Glucometer, Nova Biomedical, Waltham, MA, USA). Animals were then fasted for 6 hours and a sample of lithium heparin anticoagulated blood (100–150 μ L) was taken from a second tail clip. HbA1c was measured in 20 μ L of whole blood prior to processing to plasma (AU480; Beckman Coulter, Brea, CA, USA). Glucose, triglycerides, and cholesterol were assayed on fresh plasma samples using a clinical chemistry analyzer (AU480; Beckman Coulter, Brea, CA, USA). Oral glucose tolerance tests (OGTTs) were performed monthly after a 6-hour fast using a glucose load (2 g/kg, p.o.) and sampling from the tail at 0 (prior to glucose administration), 15, 30, 60, and 120 minutes postglucose load. The 7-week OGTT was done using blood glucose (StatStrip) methodology; plasma insulin levels were assayed at each time point of the OGTT. For subsequent OGTTs, glucose was determined from fresh plasma on the AU480 and insulin levels were determined from frozen plasma using a rat/mouse Meso Scale Discovery kit (K152BZC, Rockville, MD, USA). To insure that fasting did not negatively affect the phenotype, the fasts were limited to 6 hours (6:00 a.m.–12:00 p.m.) every two weeks.

2.4. Statistical Analysis. Data are represented as mean $\pm$ SEM. All data analysis was accomplished using JMP Statistical Software (SAS Institute). The effect of age on measured parameters (body weight, triglycerides, Cholesterol, HbA1c, NEFA, glucose, glucose AUC, insulin, and insulin AUC) was determined using one-way ANOVA with repeated measures ($P < 0.05$) and when necessary Tukey's multirange t -test was performed ($P < 0.05$). The effect of age on the 5-point oral glucose tolerance tests (OGTT) was determined using two-way ANOVA with repeated measures ($P < 0.05$). A Mahalanobis distance plot and T^2 statistic were used to identify outliers based on average fed glucose levels over the course of the study. Based on this analysis, one animal was retrospectively eliminated from analysis. A technical issue regarding the collection and processing of fasted blood samples was noted at the 17-week time point. This necessitated elimination of these samples (glucose, triglycerides, cholesterol, and insulin) from analysis. Fasting plasma glucose and insulin levels were used to calculate the homeostasis model assessment of β -cell function (HOMA- β) and insulin sensitivity index (ISI). HOMA- β was calculated as $[20 \times \text{fasting}$

TABLE 1: Profile of spontaneous hyperglycemia in individual ZDSD rats (6:00 a.m. fed BG levels, mg/dL).

Animal ID	7 weeks	9 weeks	11 weeks	13 weeks	15 weeks	17 weeks	19 weeks	21 weeks	23 weeks	25 weeks	27 weeks	29 weeks	31 weeks
1	121	130	133	149	140	112	163	230	270	375	472	487	527
2	111	130	120	133	124	129	113	129	172	234	407	487	505
3	139	146	128	158	123	138	136	237	296	341	406	443	494
4	133	125	124	137	133	160	133	313	367	405	482	537	531
6	134	127	116	151	144	140	140	172	180	324	456	463	483
7	140	131	133	146	158	197	153	438	472	502	535	523	531
8	114	131	106	131	125	147	198	301	378	408	489	495	545
9	122	144	119	152	160	292	395	394	514	541	535	593	564
10	131	154	120	162	169	265	322	404	490	451	496	592	524
11	133	123	140	168	326	405	442	511	555	544	545	536	592
12	112	123	118	141	147	207	247	411	446	461	501	566	621
13	129	138	134	146	148	265	366	453	438	507	600	502	572
14	141	143	128	157	171	199	325	386	447	493	509	540	514
15	133	126	128	134	141	278	365	436	507	544	578	526	584
16	114	135	129	148	148	178	142	97	210	322	473	427	465
17	118	117	108	138	135	149	132	169	144	371	472	457	483
18	140	123	116	133	153	176	219	140	235	121	393	391	515
19	129	131	115	141	139	158	287	363	423	451	525	511	549
20	107	142	126	188	162	107	284	379	416	463	487	541	531
21	124	141	112	143	108	114	138	189	410	424	458	472	511
22	136	129	140	133	116	120	128	225	231	295	427	454	457
23	123	129	125	138	159	132	113	124	221	180	233	303	407
24	146	131	116	140	118	207	286	397	508	494	525	575	635

Values are represented as different fonts as each animal becomes progressively hyperglycemic. Normal represents relatively normoglycemic, bold represents hyperglycemic (125–249 mg/dL), and italic represents diabetic and overtly diabetic (>250 mg/dL).

insulin ($\mu\text{U/mL}$)/fasting glucose (mmol/L) – 3.5]. Insulin sensitivity was calculated from the OGTT using Matsuda index ($1,000,000/\text{square root fasting glucose} \times \text{fasting insulin} \times \text{glucose AUC} \times \text{insulin AUC}$). Homeostatic assessment of insulin resistance (HOMA IR) was calculated using fasting glucose (mmol/L) $\times$ fasting insulin ($\mu\text{U/mL}$)/22.5 [10, 11].

3. Results

3.1. Body Weight. Male ZDSD rats weighed on average 221.9 ± 2.0 g at 7 weeks of age as study observations began. Body weights reached a plateau and peaked at 23 weeks of age (564.4 ± 8.2 g). Thereafter there was a significant ($P < 0.0001$) decline (8.2% from the peak) in body weight over the next 8 weeks (Figure 1).

3.2. Glucose. Blood glucose (BG) values in the fed state were obtained from whole blood using StatStrips. BG in male ZDSD rats progressed significantly ($P < 0.0001$) from pre-diabetic hyperglycemia to diabetic levels with age (Table 1). Most animals (56.5%) were hyperglycemic as early as 7 weeks of age with a mean fed BG of 127.4 ± 2.3 mg/dL. BG levels rose steadily, reaching 227.3 ± 21.7 and 299.91 ± 26.4 mg/dL at 19 and 21 weeks, respectively, such that most

FIGURE 1: Body weight recorded biweekly throughout the study duration of 7- to 31-week-old ZDSD rats (mean $\pm$ SEM, $n = 23$, error bars included too small to see).

animals (56.5%) could be classified as diabetic by 21 weeks. BG levels continued to increase such that 100% of animals were diabetic by 27 weeks of age (478.4 ± 15.6 mg/dL). BG levels rose to 527.8 ± 11.0 mg/dL at 31 weeks of age. Similarly,

FIGURE 2: Glucose levels were taken biweekly in fed (●) (BG) or fasted (■) plasma glucose ZDSD rats throughout the study duration of rats in ages 7 to 31 weeks (mean ± SEM, $n = 23$).

mild hyperglycemia in the fasted state was also observed in animals as young as 7 weeks of age (125.7 ± 2.1 mg/dL). Fasted plasma glucose levels remained relatively stable up to 19 weeks of age. Then significant ($P < 0.0036$) increases were noted (151.65 ± 15.4 versus 236.8 ± 27.6 mg/dL at 19 and 21 weeks, resp.). Fasted plasma glucose values progressed steadily to 498.1 ± 10.0 mg/dL in 31-week-old animals (Figure 2). Since fed blood glucose (BG) and fasted plasma glucose were taken using different methods, statistical comparison was not appropriate. Comparison of these two methods of glucose determination demonstrated that the BG levels run about 88% of the plasma glucose levels. This would effectively make the difference between fed BG and fasted plasma glucose significantly greater than what is shown in Figures 2 and 11. All animals that were analyzed in this study were overtly diabetic at the end of the study (as defined in methods above).

3.3. Glycated Hemoglobin. Chronic progressive hyperglycemia with an average fed BG level of 281.5 ± 11.1 mg/dL was confirmed as evidenced by a significant ($P < 0.0001$) increase in glycated hemoglobin (HbA1c) levels taken throughout the study period. HbA1c values in 7-week-old CRL:CD (SD) control rats ranged from 3.35 to 3.60 and remained relatively stable throughout their life span (data not shown). HbA1c levels in 7-week-old male ZDSD (3.45 ± 0.03) rats were the same as those of the control animals ($3.44 \pm 0.03\%$). Despite relatively steady morning glucose levels between 7 and 15 weeks of age (Figure 2), the HbA1c levels increased by 42% from baseline values during this period (3.45 ± 0.03 versus $4.92 \pm 0.05\%$) suggesting that there likely were unseen hyperglycemic excursions during this period (see discussion on pm glucose levels). Thereafter, HbA1c levels rose rapidly, reaching $10.88 \pm 0.23\%$ (Figure 3).

3.4. Glucose Levels during Oral Glucose Tolerance Tests. Oral glucose tolerance tests (OGTTs) were performed every four

FIGURE 3: HbA1c levels in male ZDSD rats throughout the study duration of rats in ages from 7 to 31 weeks (mean ± SEM, $n = 23$).

weeks during the experiment. For clarity purposes, only data at eight-week intervals are presented (Figure 4(a)). Significant abnormalities in glucose disposal were observed in aging ZDSD rats during performance of oral glucose tolerance tests. Glucose values taken just prior to glucose load (time zero) increased significantly ($P < 0.0001$) over time (124.9 ± 2.1 , 149.4 ± 2.4 , 314.7 ± 34.0 , and 498.1 ± 10.0 mg/dL for 7, 15, 23, and 31 weeks, resp.). Similarly, the peak glucose excursion and the glucose levels 2 hours after administration of glucose load rose dramatically as animals aged, creating a significant ($P < 0.0001$) age-dependent increase in the area under the curve ($\times 10^{-3}$ for glucose disposal, 18.4 ± 0.2 , 33.5 ± 0.4 , 58.5 ± 4.2 , and 72.1 ± 2.4 for 7, 15, 23, and 31 weeks, resp.) (Figures 4(a) and 4(b)).

3.5. Insulin Levels during Oral Glucose Tolerance Tests. In contrast to glucose values obtained during OGTT, fasted insulin values obtained just prior to glucose load increased significantly ($P < 0.0001$) in animals 7 to 19 weeks of age, after which a precipitous drop in insulin level was noted. Insulin levels in 7-week-old animals were 446.44 ± 38.9 pg/mL. Levels peaked at 19 weeks (1529.3 ± 153.3 pg/mL) and then fell significantly ($P < 0.0001$) from the peak to 189.4 ± 27.4 pg/mL in 31-week-old animals (Figure 5). In 7-week-old animals, the insulin response to glucose loading was rapid, occurring at 15 minutes, and represents a dramatic 4.3-fold increase over values prior to glucose loading (448.8 ± 37.4 versus 1935.3 ± 106.4 pg/mL). Further aging resulted in reduction of the magnitude of the insulin response in all age groups (1.7-, 1.35-, and 1.9-fold for 15, 23, and 31-week-old animals, resp.). The curve for the insulin response to glucose load revealed an increasingly flat profile as animals aged, such that insulin responses in 31-week-old animals were minimal throughout the 2-hour period. The area under the curve ($\times 10^{-3}$) for the insulin response increased significantly ($P < 0.0001$) and peaked at 19 weeks followed by a significant drop from peak in 23- ($P < 0.0016$) and 31- ($P < 0.0001$) week-old animals

FIGURE 4: (a) Glucose levels from oral glucose tolerance tests in male ZSDS rats at 7 (●), 15 (▲), 23 (◆), and 31 (■) weeks of age and (b) glucose AUC calculations for all OGTTs (mean ± SEM, $n = 23$).

FIGURE 5: Fasted insulin levels in male ZSDS rats throughout the study duration of rats in ages from 7 to 31 weeks (mean ± SEM, $n = 23$).

(118.4 ± 5.3 , 225.3 ± 17.5 , 146.5 ± 21.7 , and 32.1 ± 5.2 at 7, 19, 23, and 31 weeks, resp.) (Figures 6(a) and 6(b)).

3.6. Beta-Cell Function. Fasting plasma glucose and insulin levels obtained from OGTTs were used to calculate the homeostasis model assessment of β -cell secretory capacity. The values followed the same time course as did the fasted insulin levels presented in Figure 3, that is, a progressive increase 7–19 weeks of age, followed by a precipitous decline to values indicating very little insulin secretory capacity at 31 weeks. HOMA- β values were 3.92 ± 0.31 at 7 weeks of age, peaked at 19 weeks (12.6 ± 1.22), and fell abruptly ($P < 0.0001$) to 0.44 ± 0.1 at 31 weeks, indicating only minimal secretion at 31 weeks (Figure 7).

3.7. Insulin Sensitivity Index (ISI). Insulin sensitivity in ZSDS animals reflects the progressive hyperglycemia and augmented insulin secretion before beta cell loss as animals age. ISI in 7-week-old animals (99.3 ± 5.8) decreased quickly to 61.9 ± 7.5 at 11 weeks ($P < 0.0002$) and plateaued at 19 weeks (33.01 ± 4.7). This decline represents a significant 67% decrease in sensitivity within the 7–19 week old animals ($P < 0.0001$) (Figure 8).

3.8. Lipid Levels. Fasted triglyceride levels increased significantly ($P < 0.0001$) compared to that of 7-week-old rats and peaked at 19 weeks of age (107.5 ± 3.7 and 292.5 ± 17.8 mg/dL, resp.). A slight but not significant decrease ($P < 0.1170$) to 251.1 ± 16.7 mg/dL was apparent at 21 weeks; however, levels remained relatively stable for the remainder of the study. Average triglyceride levels were 230.3 ± 8.8 mg/dL over the last 12 weeks (Figure 9). Fasted cholesterol levels increased significantly ($P < 0.0001$) over the course of data collection, ranging from 95.4 ± 1.1 to 127.9 ± 2.4 mg/dL at 7 and 31 weeks, respectively (Figure 10).

4. Discussion

Over the last decade, there has been a global increase in obesity and type 2 diabetes (T2D). In 2011, there was an estimated 375 million people worldwide with diabetes [12]. Ninety percent of individuals with diabetes were reported as having T2D, largely the result of obesity and lack of physical activity (WHO, 1999, 2003). T2D is thought to occur, in large part, as a consequence of the development of metabolic syndrome [13] which presents as a cluster of conditions defined by obesity, insulin resistance, hypertension, hyperlipidemia, and hyperglycemia [14]. In humans, the natural course of T2D progresses from insulin resistance to compensatory hyperinsulinemia resulting in beta cell failure and overt diabetes

(a)

(b)

FIGURE 6: (a) Insulin levels from oral glucose tolerance tests in male ZSD rats at 7 (●), 15 (▲), 23 (◆), and 31 (■) weeks of age and (b) insulin AUC for all OGTTs (mean ± SEM, $n = 23$).

FIGURE 7: Calculated HOMA- β in male ZSD rats throughout the study duration of rats in ages from 7 to 31 weeks (mean ± SEM, $n = 23$).

FIGURE 9: Fasted triglycerides in male ZSD rats throughout the study duration of rats in ages from 7 to 31 weeks (mean ± SEM, $n = 23$).

FIGURE 8: Calculated ISI in male ZSD rats throughout the study duration of rats in ages from 7 to 19 weeks (mean ± SEM, $n = 23$).

[15]. Development can be initiated in humans by genetic and/or environmental factors and is thus considered a multifactorial disease [16]. Genetic polymorphisms linked to T2D have been identified in at least 3 dozen genes, most of which influence both hepatic and peripheral insulin resistance, and adipogenesis as well as beta cell mass and function [17]; however, no mutations in leptin signaling have been identified in human T2D [18, 19]. Since obesity is a major environmental factor predisposing humans to T2D [20], it becomes necessary for a translational animal model to become obese by a polygenetic mechanism.

The ZSD rat was developed to address the disparity in disease development from the human condition that is apparent in commonly used rodent models. Previous models (Zucker fatty rat, ZDF rat, *ob/ob* mice, and *db/db* mice) have

FIGURE 10: Fasted cholesterol in male ZSDS rats throughout the study duration of rats in ages from 7 to 31 weeks (mean $\pm$ SEM, $n = 23$).

proven useful in drug development and in research in the areas of obesity, metabolic syndrome, and diabetes. However, their mutations compromise the leptin pathway [21] which is essential for the normal function of CNS obesity and feeding behavior [22]. Since leptin pathway mutations are a very rare condition in the human population, the continued exclusive use of these models will impede the studies of CNS mechanisms that are central to combating the obesity conditions in the human population. The highly translational ZSDS model satisfies this important need.

The ZSDS rat model is similar to an animal model that was developed at the University of California at Davis [23, 24], in as much as it involved crossing homozygous lean ZDF rats with obese Crl:CD (SD) rats. Although direct comparisons have not been made, the model and the disease are similar to the ZSDS and thus it is probable that it will perform similarly in many experiments. The significant advantage of the ZSDS model is that it is commercially available.

The ZDF rat is the most commonly used leptin deficient rat model of metabolic syndrome, obesity, and diabetes. Obesity is severe and is apparent very early in life. Hyperglycemia with hyperinsulinemia and dyslipidemia are apparent as early as 8 weeks of age, before the animal reaches maturity, and are sustained throughout life [25, 26]. The time course for progression to beta cell failure is rapid in this model, leading to the absence of the extended metabolic syndrome (prediabetic) condition common to human T2D. Hypertension is a major contributor to the end-organ damage seen with long standing diabetes and as such is included in the cluster related to metabolic syndrome. Reports detailing blood pressure in ZDF rats vary greatly; when assessed by radio-telemetry, blood pressure is normal [27], but hypertension has been reported when pressure is assessed by tail cuff [28]. Although marked renal damage with albuminuria is also apparent with long standing diabetes [28], this model also has significant hydronephrosis which compromises its value for application. While this rat exhibits some components of metabolic syndrome, the rats progress rapidly to overt diabetes. The large divergence from the human T2D for this

model resides in the lack of a significant prediabetic period and the development of overt diabetes in the adolescent state.

In contrast to the ZDF male, the male ZSDS rat maintains a moderately long period (approximately eight weeks) of prediabetic metabolic syndrome with obesity, followed by progression to overt diabetes and its complications. This pattern is very similar to the development of T2D in humans. The female ZSDS rat does not become diabetic on ordinary rat chow such as 5008, but under the right conditions, feeding the females diabetogenic diet (5SCA or RD12468) can trip them into overt diabetes [29].

When compared to the rodent models extensively used over the past two decades, the ZSDS rat appears to be a better translational model of obesity, metabolic syndrome, and diabetes as well as its secondary complications associated with T2D. The ZSDS rat's polygenic phenotype, as it relates to metabolic syndrome, includes visceral obesity, insulin resistance, hyperglycemia, dyslipidemia, and mild hypertension [30]. In addition, ZSDS rats spontaneously develop diabetes independently of special diets or monogenic mutations making this a much more translational model. Moreover, the development of diabetes can be synchronized with the feeding of diabetogenic diets (Purina 5SCA or Research Diets 12468) beginning at 16 weeks of age; this has been described in previously published papers [29, 31–33]. As demonstrated here, the ZSDS males become spontaneously hyperglycemic when maintained on Purina 5008 and express a heterogeneous onset of overt diabetes which mimics that seen in T2D humans. When either spontaneous or synchronized diabetes is inadequately treated, this model develops the translational complications of a T2D profile with its sequelae. The resultant naturally occurring phenotype, in the presence of a functional leptin pathway, translates to a rodent model more characteristic of the disease conditions as expressed in the human population.

The characteristics of the ZSDS rat, as it goes through the prediabetic condition (metabolic syndrome) into overt diabetes, are described in this paper. From 7 to 19 weeks of age the ZSDS male rat demonstrated obesity, impaired glucose tolerance, dyslipidemia, and prediabetic hypertension [30]. Time dependent elevation in HbA1c, which occurs during the metabolic syndrome/prediabetic phase, was also noted. Although the morning fed glucose levels are quite stable in animals 7–15 weeks of age, they are higher than those in control rats; this study did not include blood glucose from control animals. More recent data using continuous blood glucose monitoring and StatStrip reading in the am and pm have reliably demonstrated that afternoon glucose levels are significantly higher than the morning levels in this model [11]. This is most likely a representation of the abnormal feeding pattern of ZSDS rats. They are not strictly nocturnal feeders and tend to eat a significant amount during the day [34]. It should also be noted that the late afternoon glucose elevations might be related to the human dawn effect since late afternoon just before lights go off is equivalent to the rat's morning since they are nocturnal animals.

As metabolic syndrome developed in the ZSDS rat, insulin levels increased in a compensatory fashion to combat increasing insulin resistance. Shortly after the peak in

insulin levels at 19 weeks of age, insulin values fell precipitously as beta cells began to fail. Progressive decreases in beta cell secretory capacity were demonstrated by the dramatic decrease in insulin and in HOMA- β calculated during this time. As the ZSDS model became more diabetic, further abnormalities in glucose disposal became apparent as the magnitude and duration of the glucose excursion following glucose load are increased with age, while the magnitude of the insulin response is minimized. Area under the glucose curve in the OGTT increased while area under the insulin curve was drastically diminished. In fact, in 31-week-old animals, the insulin response to glucose load was barely visible. The pattern of changes in glucose homeostasis in ZSDS is very much like that in humans as the disease progressed. Initially, obesity leads to insulin resistance due to many factors, including contributions from adipokines and cytokines from visceral fat. Glucose levels are temporarily maintained at normal level through hypersecretion of insulin from beta cells. Insulin resistance continues to progress until beta cells begin to cease functioning, insulin levels drop, and overt diabetes ensues.

Metabolic dysregulation in patients with metabolic syndrome includes hypertriglyceridemia. Similar to patients, progressive elevations in triglyceride levels were apparent in ZSDS rats. Cholesterol levels increased as animals age; interestingly, the rate of increase changed upward as ZSDS rats became overtly diabetic. Furthermore, although this study does not demonstrate the long-term complications of diabetes, we believe that this model will also develop complications that are seen in the human population with long-lasting, inadequately controlled diabetes. Indeed, in other studies, the ZSDS rat has been shown to develop diabetic osteoporosis [33], diabetic nephropathy [35], diabetic connective tissue changes [29, 32], and diabetic neuropathy [36] and hypertension prior to development of diabetes [30].

A review of the literature on the development of T2D in the human population demonstrated a high degree of translation with the ZSDS model. The review and analysis by many authors have led them to an understanding of the time course of events that occur in humans in the prediabetic and diabetic conditions [15, 37–39]. Figure 11(a) captures this in a single graphic that represents the progression of the “natural history of type 2 diabetes” in the human population. This figure produced by Kendall and Bergenstal represents the changes that occur during the prediabetic stages through the overt diabetic stages of diabetes. Similar to Figures 11(a) and 11(b) graphs from this paper have combined to compare the pattern which is observed in ZSDS rats where insulin resistance is represented by the progressive decrease in glucose disposal (increase glucose AUC) and insulin response is represented by the insulin response to a glucose load during an OGTT. Insulin AUC in the prediabetic state is exaggerated while a steady decline in insulin response is noted during the diabetic state.

The current study demonstrates similarities in fasting and fed glucose levels (Figure 2), insulin levels (Figure 5), the insulin AUC (Figure 6), and the HOMA- β (Figure 7) in the progression of the disease from the prediabetic state to the overt diabetic state. This comparison appears to support

FIGURE 11: (a) The upper panel shows the graphic representation of the progression of both fasting and postmeal hyperglycemia. The lower panel demonstrates both insulin resistance and defective beta-cell function (Natural History of Type 2 Diabetes © 2010, International Diabetes Center, Minneapolis, MN, USA, used with permission). (b) demonstrates the similarity between the progression of diabetes between the human condition and ZSDS rat. The vertical dotted line represents the onset of diabetes.

the case for translatability of the progression of T2D in ZSDS model to the human disease.

5. Conclusions

The ZSDS rat model exhibits all stages and multiple components of metabolic syndrome/T2D and the complications of these conditions. Although further research is clearly needed, this study demonstrates that the ZSDS model may represent a truly translational model for the investigation of causative mechanisms, targeted interventions, and treatments for this

multifaceted disease. The expression of diabetic complications in ZSDS rats may strengthen the model's translatability. The authors believe that, in addition to the scientific merits of the ZSDS, the use of the ZSDS in the "one rat, many models" paradigm presents an opportunity for investigators to significantly reduce costs while evaluating compound effects on the multiple components of T2D and its sequelae.

Conflict of Interests

Richard G. Peterson is the developer of the ZSDS rat and could gain financially as a result of the marketing of this animal model. The other authors declare that there is no conflict of interests regarding the publication of this paper.

References

- [1] G. Kim and S. Caprio, "Diabetes and insulin resistance in pediatric obesity," *Pediatric Clinics of North America*, vol. 58, no. 6, pp. 1355–1361, 2011.
- [2] A. Friend, L. Craig, and S. Turner, "The prevalence of metabolic syndrome in children: a systematic review of the literature," *Metabolic Syndrome and Related Disorders*, vol. 11, no. 2, pp. 71–80, 2013.
- [3] M. D. DeBoer, "Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: need for screening tools to target interventions," *Nutrition*, vol. 29, no. 2, pp. 379–386, 2013.
- [4] S. Devaraj, M. M. Swarbrick, U. Singh, B. Adams-Huet, P. J. Havel, and I. Jialal, "CRP and adiponectin and its oligomers in the metabolic syndrome : evaluation of new laboratory-based biomarkers," *American Journal of Clinical Pathology*, vol. 129, no. 5, pp. 815–822, 2008.
- [5] O. Timar, F. Sestier, and E. Levy, "Metabolic syndrome X: a review," *Canadian Journal of Cardiology*, vol. 16, no. 6, pp. 779–789, 2000.
- [6] B. E. Levin, A. A. Dunn-Meynell, B. Balkan, and R. E. Keeseey, "Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats," *American Journal of Physiology*, vol. 273, no. 2, part 2, pp. R725–R730, 1997.
- [7] B. E. Levin, A. A. Dunn-Meynell, J. E. McMin, M. Alperovich, A. Cunningham-Bussell, and S. C. Chua Jr., "A new obesity-prone, glucose-intolerant rat strain (F.DIO)," *The American Journal of Physiology—Regulatory Integrative and Comparative Physiology*, vol. 285, no. 5, pp. R1184–R1191, 2003.
- [8] S. C. Griffen, J. Wang, and M. S. German, "A genetic defect in β -cell gene expression segregates independently from the fa locus in the ZDF rat," *Diabetes*, vol. 50, no. 1, pp. 63–68, 2001.
- [9] W. D. Winter, J. DeJongh, T. Post et al., "A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus," *Journal of Pharmacokinetics and Pharmacodynamics*, vol. 33, no. 3, pp. 313–343, 2006.
- [10] E. Cersosimo, C. Solis-Herrera, M. E. Trautmann, J. Malloy, and C. L. Triplitt, "Assessment of pancreatic β -cell function: review of methods and clinical applications," *Current Diabetes Reviews*, vol. 10, no. 1, pp. 2–42, 2014.
- [11] T. Coskun, L. O'Farrell, R. Brockway, P. Haefner, R. G. Peterson, and C. V. Jackson, "Continuous Glucose Monitoring via Telemetry in Rat (Late Breaking Abstract of Poster Presented at June 21-25, 2013 meeting of the ADA)," 2013.
- [12] G. Danaei, M. M. Finucane, Y. Lu et al., "National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants," *The Lancet*, vol. 378, no. 9785, pp. 31–40, 2011.
- [13] G. M. Reaven, "Role of insulin resistance in human disease," *Diabetes*, vol. 37, no. 12, pp. 1595–1607, 1988.
- [14] E. Kassi, P. Pervanidou, G. Kaltsas, and G. Chrousos, "Metabolic syndrome: definitions and controversies," *BMC Medicine*, vol. 9, article 48, 2011.
- [15] R. A. DeFronzo, "Pathogenesis of type 2 diabetes mellitus," *Medical Clinics of North America*, vol. 88, no. 4, pp. 787–835, 2004.
- [16] P. Poulsen, K. Ohm Kyvik, A. Vaag, and H. Beck-Nielsen, "Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance—a population-based twin study," *Diabetologia*, vol. 42, no. 2, pp. 139–145, 1999.
- [17] A. Brunetti, E. Chiefari, and D. Foti, "Recent advances in the molecular genetics of type 2 diabetes mellitus," *World Journal of Diabetes*, vol. 5, no. 2, pp. 128–140, 2014.
- [18] W. Jin and M.-E. Patti, "Genetic determinants and molecular pathways in the pathogenesis of Type 2 diabetes," *Clinical Science*, vol. 116, no. 2, pp. 99–111, 2009.
- [19] B. Jafar-Mohammadi and M. I. McCarthy, "Genetics of type 2 diabetes mellitus and obesity—a review," *Annals of Medicine*, vol. 40, no. 1, pp. 2–10, 2008.
- [20] A. Chatzigeorgiou, A. Halapas, K. Kalafatakis, and E. F. Kamper, "The use of animal models in the study of diabetes mellitus," *In Vivo*, vol. 23, no. 2, pp. 245–258, 2009.
- [21] B. Wang, P. C. Chandrasekera, and J. J. Pippin, "Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes," *Current Diabetes Reviews*, vol. 10, no. 2, pp. 131–145, 2014.
- [22] D. F. Patton and R. E. Mistlberger, "Circadian adaptations to meal timing: neuroendocrine mechanisms," *Frontiers in Neuroscience*, vol. 7, article 185, 2013.
- [23] B. P. Cummings, E. K. Digitale, K. L. Stanhope et al., "Development and characterization of a novel rat model of type 2 diabetes mellitus: the UC Davis type 2 diabetes mellitus UCD-T2DM rat," *The American Journal of Physiology: Regulatory Integrative and Comparative Physiology*, vol. 295, no. 6, pp. R1782–R1793, 2008.
- [24] A. M. Rountree, B. J. Reed, B. P. Cummings et al., "Loss of coupling between calcium influx, energy consumption and insulin secretion associated with development of hyperglycaemia in the UCD-T2DM rat model of type 2 diabetes," *Diabetologia*, vol. 56, no. 4, pp. 803–813, 2013.
- [25] Z. Szöcs, B. Brunmair, K. Stadlbauer et al., "Age-dependent development of metabolic derangement and effects of intervention with pioglitazone in Zucker diabetic fatty rats," *Journal of Pharmacology and Experimental Therapeutics*, vol. 326, no. 1, pp. 323–329, 2008.
- [26] H. L. Schäfer, W. Linz, E. Falk et al., "AVE8134, a novel potent PPAR α agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats," *Acta Pharmacologica Sinica*, vol. 33, no. 1, pp. 82–90, 2012.
- [27] G. Cao, T. P. Beyer, Y. Zhang et al., "Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure," *Journal of Lipid Research*, vol. 52, no. 12, pp. 2169–2176, 2011.

- [28] M. A. Hye Khan, J. Neckar, J. Haines, and J. D. Imig, "Azilsartan improves glycemic status and reduces kidney damage in Zucker diabetic fatty rats," *The American Journal of Hypertension*, vol. 27, no. 8, pp. 1087–1095, 2014.
- [29] A. D. Gonzalez, M. A. Gallant, D. B. Burr, and J. M. Wallace, "Multiscale analysis of morphology and mechanics in tail tendon from the ZDSD rat model of type 2 diabetes," *Journal of Biomechanics*, vol. 47, no. 3, pp. 681–686, 2014.
- [30] D. M. Eaton III, A. N. Rogers, A. E. Rice, K. Coy, R. G. Peterson, and C. S. Packer, "Relationship between dyslipidemia and hypertension (HBP) in male ZDSD, a new rat model of metabolic syndrome (MetS)," *The FASEB Journal*, vol. 27, p. 1190.1, 2013.
- [31] J. E. Davis, J. Cain, W. J. Banz, and R. G. Peterson, "Age-related differences in response to high-fat feeding on adipose tissue and metabolic profile in ZDSD rats," *ISRN Obesity*, vol. 2013, Article ID 584547, 8 pages, 2013.
- [32] M. A. Hammond, M. A. Gallant, D. B. Burr, and J. M. Wallace, "Nanoscale changes in collagen are reflected in physical and mechanical properties of bone at the microscale in diabetic rats," *Bone*, vol. 60, pp. 26–32, 2013.
- [33] S. Reinwald, R. G. Peterson, M. R. Allen, and D. B. Burr, "Skeletal changes associated with the onset of type 2 diabetes in the ZDF and ZDSD rodent models," *American Journal of Physiology—Endocrinology and Metabolism*, vol. 296, no. 4, pp. E765–E774, 2009.
- [34] C. Jackson, R. Peterson, D. Compton, E. Ulman, S. Tiesma, and R. Brockway, "Continuous glucose and food intake monitoring in the male ZDSD rat: comparison of normal and high fat diets," *The FASEB Journal*, vol. 28, supplement 1, p. 1051.12, 2014.
- [35] R. G. Peterson, K. M. Zimmerman, and V. H. Gattone, "The ZDSD rat, a translational model of obesity, metabolic syndrome and diabetes that expresses the characteristics of human diabetic nephropathy (abstract)," *Journal of the American Society of Nephrology*, vol. 22, p. 240A, 2011.
- [36] E. P. Davidson, L. J. Coppey, A. Holmes et al., "Characterization of diabetic neuropathy in the Zucker diabetic Sprague-Dawley (ZDSD) rat: a new animal model for type 2 diabetes," *Journal of Diabetes Research*, vol. 2014, Article ID 714273, 2014.
- [37] R. A. DeFronzo, "Lilly lecture 1987: the triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM," *Diabetes*, vol. 37, no. 6, pp. 667–687, 1988.
- [38] R. A. DeFronzo, "From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus," *Diabetes*, vol. 58, no. 4, pp. 773–795, 2009.
- [39] E. Ferrannini, M. Nannipieri, K. Williams, C. Gonzales, S. M. Haffner, and M. P. Stern, "Mode of onset of type 2 diabetes from normal or impaired glucose tolerance," *Diabetes*, vol. 53, no. 1, pp. 160–165, 2004.